Literature DB >> 15060215

Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children.

Ian C Michelow1, Kurt Olsen, Juanita Lozano, Nancy K Rollins, Lynn B Duffy, Thedi Ziegler, Jaana Kauppila, Maija Leinonen, George H McCracken.   

Abstract

OBJECTIVES: The precise epidemiology of childhood pneumonia remains poorly defined. Accurate and prompt etiologic diagnosis is limited by inadequate clinical, radiologic, and laboratory diagnostic methods. The objective of this study was to determine as precisely as possible the epidemiology and morbidity of community-acquired pneumonia in hospitalized children.
METHODS: Consecutive immunocompetent children hospitalized with radiographically confirmed lower respiratory infections (LRIs) were evaluated prospectively from January 1999 through March 2000. Positive blood or pleural fluid cultures or pneumolysin-based polymerase chain reaction assays, viral direct fluorescent antibody tests, or viral, mycoplasmal, or chlamydial serologic tests were considered indicative of infection by those organisms. Methods for diagnosis of pneumococcal pneumonia among study subjects were published by us previously. Selected clinical characteristics, indices of inflammation (white blood cell and differential counts and procalcitonin values), and clinical outcome measures (time to defervescence and duration of oxygen supplementation and hospitalization) were compared among groups of children.
RESULTS: One hundred fifty-four hospitalized children with LRIs were enrolled. Median age was 33 months (range: 2 months to 17 years). A pathogen was identified in 79% of children. Typical respiratory bacteria were identified in 60% (of which 73% were Streptococcus pneumoniae), viruses in 45%, Mycoplasma pneumoniae in 14%, Chlamydia pneumoniae in 9%, and mixed bacterial/viral infections in 23%. Preschool-aged children had as many episodes of atypical bacterial LRIs as older children. Children with typical bacterial or mixed bacterial/viral infections had the greatest inflammation and disease severity. Multivariate logistic-regression analyses revealed that high temperature (> or = 38.4 degrees C) within 72 hours after admission (odds ratio: 2.2; 95% confidence interval: 1.4-3.5) and the presence of pleural effusion (odds ratio: 6.6; 95% confidence interval: 2.1-21.2) were significantly associated with bacterial pneumonia.
CONCLUSIONS: This study used an expanded diagnostic armamentarium to define the broad spectrum of pathogens that cause pneumonia in hospitalized children. The data confirm the importance of S pneumoniae and the frequent occurrence of bacterial and viral coinfections in children with pneumonia. These findings will facilitate age-appropriate antibiotic selection and future evaluation of the clinical effectiveness of the pneumococcal conjugate vaccine as well as other candidate vaccines.

Entities:  

Mesh:

Year:  2004        PMID: 15060215     DOI: 10.1542/peds.113.4.701

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  222 in total

1.  Utilization of viral molecular diagnostics among children hospitalized with community acquired pneumonia.

Authors:  Grant S Schulert; Paul D Hain; Derek J Williams
Journal:  Hosp Pediatr       Date:  2014-11

2.  Diagnostic utility and clinical significance of naso- and oropharyngeal samples used in a PCR assay to diagnose Mycoplasma pneumoniae infection in children with community-acquired pneumonia.

Authors:  Ian C Michelow; Kurt Olsen; Juanita Lozano; Lynn B Duffy; George H McCracken; R Doug Hardy
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

3.  Unveiling the burden of influenza-associated pneumococcal pneumonia.

Authors:  Carlos G Grijalva; Marie R Griffin
Journal:  J Infect Dis       Date:  2011-12-07       Impact factor: 5.226

4.  Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland.

Authors:  M Patrzałek; P Albrecht; M Sobczynski
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-01       Impact factor: 3.267

5.  Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among mycoplasma pneumoniae strains.

Authors:  Chonnamet Techasaensiri; Claudia Tagliabue; Marianna Cagle; Pooya Iranpour; Kathy Katz; Thirumalai R Kannan; Jacqueline J Coalson; Joel B Baseman; R Doug Hardy
Journal:  Am J Respir Crit Care Med       Date:  2010-05-27       Impact factor: 21.405

6.  Identification of bacterial pathogens in pediatric community-acquired lower respiratory tract infection using a simplified procedure of sputum sampling and examination: comparison between hospitalized children with and without underlying diseases.

Authors:  T Hoshina; K Kusuhara; T Takimoto; M Saito; T Hara
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-02-24       Impact factor: 3.267

7.  Viridans streptococci causing community acquired pneumonia.

Authors:  M Freitas; A Castelo; G Petty; C E Gomes; E Carvalho
Journal:  Arch Dis Child       Date:  2006-05-31       Impact factor: 3.791

8.  Response to: Bacterial co-infection and the interpretation of immunological data from BAL fluid specimens in severe RSV bronchiolitis (Thorax 2006;61:1098).

Authors:  K Thorburn
Journal:  Thorax       Date:  2007-03       Impact factor: 9.139

9.  Respiratory tract infection with Mycoplasma pneumoniae in interleukin-12 knockout mice results in improved bacterial clearance and reduced pulmonary inflammation.

Authors:  C M Salvatore; M Fonseca-Aten; K Katz-Gaynor; A M Gomez; A Mejias; C Somers; S Chavez-Bueno; G H McCracken; R D Hardy
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

10.  Hyperoside inhibits proinflammatory cytokines in human lung epithelial cells infected with Mycoplasma pneumoniae.

Authors:  Fang Liu; YuHua Zhao; JieMin Lu; ShuangHui Chen; XinGuang Zhang; WenWei Mao
Journal:  Mol Cell Biochem       Date:  2018-10-22       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.